Bristol Myers

Bristol-Myers CEO Says the Company Is in Transition

Bloomberg Television

Bristol Myers Squibb - History and Company profile (overview)

Companies History

Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug

CNBC Television

Bristol-Myers Squibb - Addressing the Unmet Needs of NASH Patients

WebsEdgeMedicine

Bristol Myers Squibb Stock Analysis | Best Pharma Stocks For Long Term Investors?

David Marquez - Personal Finance & Investing

[Jun24@6:50PM] $BMY (Bristol-Myers Squibb)

Bristol Myers Plans to Launch Nine New Drugs, CEO Says

Bloomberg Television

U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment...

Bristol Myers Squibb CEO on cancer drug pipeline

CNBC Television

Bristol Myers to buy Karuna Therapeutics for $14 billion

CNBC Television

6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity? | FAST Graphs

Bristol Myers Squibb to buy Karuna Therapeutics for $14 billion in cash

CNBC Television

Why is Bristol Myers Squibb blocking Americans from accessing more affordable generics?

Senator Bernie Sanders

Shaping more sustainable IT procurement with Lenovo and Bristol Myers Squibb

The state of pharmaceuticals: Bristol-Myers Squibb's plan to buy RayzeBio

CNBC Television

The Cell Therapy Process (BMS Cell Therapy Manufacturing Tour)

Bristol Myers Squibb

Bristol Myers Squibb | Global Patient Week 2023: LinkedIn Live

Bristol Myers Squibb

Bristol Myers Squibb | Patient Stories: Meet Carlos

Bristol Myers Squibb

Bristol Myers Squibb | Flexible Ways of Working

Bristol Myers Squibb